Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype
Muni Hu(Shanghai Jiao Tong University), Haoyan Chen(Shanghai Jiao Tong University), Baoqin Xuan(Shanghai Jiao Tong University), Jie Hong(Shanghai Jiao Tong University), Jinmei Ding(Shanghai Jiao Tong University), Xiaoqiang Zhu(Shanghai Jiao Tong University), Lingxi Li(Shanghai Institute of Hematology), Xiuying Xiao(Shanghai Jiao Tong University), Yanru Ma(Shanghai Jiao Tong University), Lijun Ning(Shanghai Institute of Hematology), Xiaowen Huang(Renji Hospital), Huimin Chen(Renji Hospital), Hua Li(Shanghai Jiao Tong University), Zhenyu Wang(Henan Provincial People's Hospital), Ying Zhao(Shanghai Jiao Tong University), Jiantao Li(Guangdong Ocean University), Youwei Zhang(Shanghai University), Yi Jiang(Union Hospital), Ye Hu(Arizona State University), Tianying Tong(Shanghai Jiao Tong University), Jing‐Yuan Fang(Shanghai Institute of Hematology), Yue Zhang(First Hospital of Lanzhou University), Yilu Zhou(Shanghai Jiao Tong University)
Cited by 10
Related Papers
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
Roles of Chk1 in cell biology and cancer therapy
|International Journal of Cancer|2013|456
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|427
Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts
|Nature Communications|2023|231